Combination of PD-1 blockade and RetroNectin®-activated cytokine-induced killer in preheavily treated non-small-cell lung cancer: a retrospective study. (23rd October 2018)

• Record Type: Journal Article
• Authors: Zhao, Lingdi; Han, Lu; Zhang, Yong; Li, Tiepeng; Yang, Yonghao; Li, Wei; Shang, Yiman; Lin, Hongwei; Gao, Quanli
• Is Part Of: Immunotherapy. Volume 10:Number 15(2018)
• Page Start: 1315
• Page End: 1323
• Publication Date: 2018-10-23
• Subjects: adoptive cell immunotherapy -- anti-PD-1 -- carcinoma -- combination -- non-small-cell lung; Immunotherapy -- Periodicals; 615.37
• DOI: 10.2217/imt-2018-0125
• Languages: English
• ISSNs: 1750-743X

Abstract

Aim: To analyze the efficacy of PD-1 blockade combined with RetroNectin ® -activated cytokine-induced killer (R-CIK) cells in preheavily treated advanced non-small-cell lung cancer (NSCLC).Methods: We retrospectively analyzed patients with advanced NSCLC who received PD-1 blockade combined with R-CIK cells whose treatments failed at least two regimens.Results: The median number of previous treatment regimens was three (range: 2–7). Partial remission was achieved in two patients, stable disease in four patients and one patient experienced progressive disease. The median time-to-progression was 4.8 months.Conclusion: PD-1 blockade combined with R-CIK cells is safe and effective in patients with advanced NSCLC who have failed at least two treatment regimens.